EHNA
From Wikipedia, the free encyclopedia
 |
|
|
EHNA
|
|
| Systematic (IUPAC) name | |
| 3-(6-aminopurin-9-yl)nonan-2-ol hydrochloride | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C14H24ClN5O |
| Mol. mass | 313.826 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) is a phosphodiesterase inhibitor that selectively inhibits phosphodiesterase type-2 (PDE2).[1]
[edit] References
- ^ Podzuweit T, Nennstiel P and Muller A (1995)Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal. 7:733-8. PMID 8519602
| Selective Phosphodiesterase inhibitors (C01CE, G04BE) | |
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Mesembrine, Rolipram |
| PDE5 | Sildenafil, Tadalafil, Vardenafil |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
